A new study1 from the RECOVERY Collaborative Group adds another piece to the puzzle of severe COVID-19 therapy. The RECOVERY trials have been pivotal in providing evidence on the efficacy of compounds within current treatment guidelines for COVID-19, such as dexamethasone, tocilizumab, and the casirivimab and imdevimab combination.1–3 In previous randomised trials, these monoclonal antibodies4 were effective in preventing infection and clinical progression when given in the early phase of infection.